Back to Search Start Over

Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals.

Authors :
Sabbagh Q
Haghshenas S
Piard J
Trouvé C
Amiel J
Attié-Bitach T
Balci T
Barat-Houari M
Belonis A
Boute O
Brightman DS
Bruel AL
Caraffi SG
Chatron N
Collet C
Dufour W
Edery P
Fong CT
Fusco C
Gatinois V
Gouy E
Guerrot AM
Heide S
Joshi A
Karp N
Keren B
Lesieur-Sebellin M
Levy J
Levy MA
Lozano C
Lyonnet S
Margot H
Marzin P
McConkey H
Michaud V
Nicolas G
Nizard M
Paulet A
Peluso F
Pernin V
Perrin L
Philippe C
Prasad C
Prasad M
Relator R
Rio M
Rondeau S
Ruault V
Ruiz-Pallares N
Sanchez E
Shears D
Siu VM
Sorlin A
Tedder M
Tharreau M
Mau-Them FT
van der Laan L
Van Gils J
Verloes A
Whalen S
Willems M
Yauy K
Zuntini R
Kerkhof J
Sadikovic B
Geneviève D
Source :
Genetics in medicine : official journal of the American College of Medical Genetics [Genet Med] 2024 Jan; Vol. 26 (1), pp. 101007. Date of Electronic Publication: 2023 Oct 17.
Publication Year :
2024

Abstract

Purpose: BCL11B-related disorder (BCL11B-RD) arises from rare genetic variants within the BCL11B gene, resulting in a distinctive clinical spectrum encompassing syndromic neurodevelopmental disorder, with or without intellectual disability, associated with facial features and impaired immune function. This study presents an in-depth clinico-biological analysis of 20 newly reported individuals with BCL11B-RD, coupled with a characterization of genome-wide DNA methylation patterns of this genetic condition.<br />Methods: Through an international collaboration, clinical and molecular data from 20 individuals were systematically gathered, and a comparative analysis was conducted between this series and existing literature. We further scrutinized peripheral blood DNA methylation profile of individuals with BCL11B-RD, contrasting them with healthy controls and other neurodevelopmental disorders marked by established episignature.<br />Results: Our findings unveil rarely documented clinical manifestations, notably including Rubinstein-Taybi-like facial features, craniosynostosis, and autoimmune disorders, all manifesting within the realm of BCL11B-RD. We refine the intricacies of T cell compartment alterations of BCL11B-RD, revealing decreased levels naive CD4 <superscript>+</superscript> T cells and recent thymic emigrants while concurrently observing an elevated proportion of effector-memory expressing CD45RA CD8 <superscript>+</superscript> T cells (TEMRA). Finally, a distinct DNA methylation episignature exclusive to BCL11B-RD is unveiled.<br />Conclusion: This study serves to enrich our comprehension of the clinico-biological landscape of BCL11B-RD, potentially furnishing a more precise framework for diagnosis and follow-up of individuals carrying pathogenic BCL11B variant. Moreover, the identification of a unique DNA methylation episignature offers a valuable diagnosis tool for BCL11B-RD, thereby facilitating routine clinical practice by empowering physicians to reevaluate variants of uncertain significance within the BCL11B gene.<br />Competing Interests: Conflict of Interest The authors declare no conflicts of interest.<br /> (Copyright © 2023 American College of Medical Genetics and Genomics. All rights reserved.)

Details

Language :
English
ISSN :
1530-0366
Volume :
26
Issue :
1
Database :
MEDLINE
Journal :
Genetics in medicine : official journal of the American College of Medical Genetics
Publication Type :
Academic Journal
Accession number :
37860968
Full Text :
https://doi.org/10.1016/j.gim.2023.101007